As a US government organization funded by the taxpayers, one would think that NASA is one of the most well-funded bodies in the world. However, it turns out that the space agency is far too broke to send people to Mars, contradicting what the Trump administration recently touted. Now, the only hope of humanity becoming a multi-planet species is SpaceX, which does have money.
There’s no denying that an endeavor like sending people to Mars would be a costly one and with the US political climate being what it is, committing resources to something that a lot of people believe is non-essential would be incredibly unpopular. In the case of NASA, the agency recently admitted during a meeting that even landing on Mars is beyond them.
"I can't put a date on humans on Mars, and the reason really is the other piece is, at the budget levels we described, this roughly 2 percent increase, we don’t have the surface systems available for Mars," William H. Gerstenmaier, the head of human spaceflight at NASA said. "And that entry, descent and landing is a huge challenge for us for Mars."
As Ars Technica notes, there were plenty of skeptics and naysayers who doubted that NASA even had the time or the capability to send people to Mars when the goal was announced. After this admission, those people just got, even more, ammunition to hurl towards the space agency.
For the most part, it would seem that some of the biggest obstacles that prevent the US space agency from achieving such a goal are the costs that its current rocket technology would incur. Unlike what SpaceX has already achieved, NASA does not have reusable rockets.
This would make launches incredibly expensive, and landing on Mars would be out of the question. Basically, as of this moment, Elon Musk’s private space company is the best hope that humanity has.


Senate Sets December 8 Vote on Trump’s NASA Nominee Jared Isaacman
NASA Astronauts Wilmore and Williams Recover After Boeing Starliner Delay
Kennedy Sets September Deadline to Uncover Autism Causes Amid Controversy
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Astronomers have discovered another puzzling interstellar object − this third one is big, bright and fast
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now
FDA Adds Fatal Risk Warning to J&J and Legend Biotech’s Carvykti Cancer Therapy
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug 



